journal
Journal For International Medical Graduates
Journal For International Medical Graduates
California Institute of Behavioral Neurosciences and Psychology
US
https://www.cibnp.com
2832-9864
154
Articles
Impact of Pharmacogenomics Testing on Response to Antidepressants and Antipsychotics – A Systematic Review
Sarah Alhaddad
Alhaddad
Sarah
sarah.alhaddad@jimgs.com
Christian Paulsingh
Paulsingh
Christian
christian.paulsingh@jimgs.com
Faisal Riaz
Riaz
Faisal
faisal.riaz@jimgs.com
Gourav Garg
Garg
Gourav
gourav.garg@jimgs.com
Lotanna Umeano
Umeano
Lotanna
lotanna.umeano@jimgs.com
Sadaf Iftikhar
Iftikhar
Sadaf
sadaf.ıftikhar@jimgs.com
Tuheen Sanker Nath
Nath
Tuheen Sanker
tuheen.sanker.nath@jimgs.com
18
04
2024
Received: 1842024
Copyright (c) 2024 Journal For International Medical Graduates
2024
Journal For International Medical Graduates
Precision medicine
personalized medicine
pharmacogenomics testing
individualized medicine
predictive medicine and Antidepressant Drug
[
Ornstein SM, Nietert PJ, Jenkins RG, Litvin CB. The prevalence of chronic diseases and multimorbidity in primary care practice: a PPRNet report. J Am Board Fam Med. 2013 Sep-Oct;26(5):518-24. doi: 10.3122/jabfm.2013.05.130012.
]
[
Brody DJ, Gu Q. Antidepressant Use Among Adults: United States, 2015-2018. NCHS Data Brief. 2020 Sep;(377):1-8. https://pubmed.ncbi.nlm.nih.gov/33054926.
]
[
Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018 Apr 1;75(4):336-346. doi: 10.1001/jamapsychiatry.2017.4602.
]
[
Jameson JL, Longo DL. Precision medicine — personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229–2234.doi:10.1056/NEJMsb150310426014593.
]
[
Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507.doi:10.1038/nrg.2016.8627528417.
]
[
Tonelli MR, Shirts BH. Knowledge for precision medicine: mechanistic reasoning and methodological pluralism. JAMA. 2017;318(17):1649–1650. doi:10.1001/jama.2017.1191429052.
]
[
Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011 Aug;31(4):512-6. doi: 10.1097/JCP.0b013e3182228619.
]
[
Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008 Jan;75(1):57-66. doi: 10.3949/ccjm.75.1.57.
]
[
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an Updated Guideline for Reporting Systematic Reviews. British Medical Journal. 2021 Mar 29;372(71). doi: 10.1136/bmj.n71.
]
[
Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928. doi: 10.1136/bmj.d5928.
]
[
Forester BP, Parikh SV, Weisenbach S, et al. Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression. Am J Geriatr Psychiatry. 2020 Sep;28(9):933-945. doi: 10.1016/j.jagp.2020.05.005. Epub 2020 May 19.
]
[
van der Schans, J., Hak, E., Postma, M, et al. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial). Journal of Clinical Psychopharmacology, 39(6), 583-590. https://doi.org/10.1097/JCP.0000000000001129.
]
[
Vande Voort JL, Orth SS, Shekunov J, et al. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):46-55. doi: 10.1016/j.jaac.2021.03.011. Epub 2021 Jun 5.
]
[
Greden JF, Parikh SV, Rothschild AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019 Apr;111:59-67. doi: 10.1016/j.jpsychires.2019.01.003. Epub 2019 Jan 4.
]
[
Thase ME, Parikh SV, Rothschild AJ, et al. Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial. J Clin Psychiatry. 2019 Oct 31;80(6):19m12910. doi: 10.4088/JCP.19m12910.
]
[
Papastergiou J, Quilty LC, Li W, et al. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clin Transl Sci. 2021 Jul;14(4):1359-1368. doi: 10.1111/cts.12986. Epub 2021 Feb 28.
]
[
Tiwari AK, Zai CC, Altar CA, et al. Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry. 2022 Mar 14;12(1):101. doi: 10.1038/s41398-022-01847-8. Erratum in: Transl Psychiatry. 2022 May 30;12(1):214.
]
[
Perlis RH, Dowd D, Fava M, Lencz T, Krause DS. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety. 2020 Sep;37(9):834-841. doi: 10.1002/da.23029. Epub 2020 May 7.
]
[
McCarthy MJ, Chen Y, Demodena A, et al. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol. 2021 Aug;35(8):992-1002. doi: 10.1177/02698811211015224. Epub 2021 May 3.
]
[
Engelmann J, Zillich L, Frank J, et al. Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial. Transl Psychiatry. 2022 Jul 7;12(1):268. doi: 10.1038/s41398-022-02032-7.
]